Oncology and Carcinogenesis articles for People's Liberation Army (PLA), China

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 162

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
10 1.43
Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer 0.08
An Intracellular Gelated Macrophage-Based Vaccine for Tumor Immunotherapy 0.10
Charge-Reversal Near-Infrared II Polymeric Amphiphiles Enable Efficient Combinatorial Gene and Mild Photothermal Therapy for Osteosarcoma 0.45
Immunological Conversion of Solid Tumors Using an Outer Membrane Vesicle Based Checkpoint Nanoinhibitor for Cancer Immunotherapy 0.12
Rapid Detection and Purification of Extracellular Vesicles for Hepatocellular Carcinoma Screening Using a Plasmonic Metasurface Integrated with the Kolmogorov–Arnold Network 0.15
Nanotentacle-Armed Flexible Affinity Interface Enables Streamlined Capture, Labeling, and Release of Circulating Tumor Cells 0.22
In Situ Ultrasound-Triggered Bioluminescence for Combined Sono/Photodynamic Immunotherapy 0.11
Machine Learning-Assisted Multimodal Early Screening of Lung Cancer Based on a Multiplexed Laser-Induced Graphene Immunosensor 0.07
A Nitroreductase-Responsive Type I Photosensitizer with Aggregation-Induced Emission Characteristics for Precise Hypoxic Cancer Theranostics 0.04
Combretastatin A4-Based Albumin Nanoparticles Remodeling the Tumor Immune Microenvironment to Enhance T Cell Immunotherapy in Colon Cancer 0.08
2 1.85
A Neuraminidase-Functionalized Injectable Hydrogel Depletes Sialic Acid to Disrupt the Tumor–Osteoclast Cycle and Suppress Breast Cancer Bone Metastasis 1.00
Cascade-targeting oxygen-self-supplying nano-photosensitizer for enhanced photodynamic immunotherapy of triple-negative breast cancer 0.85
3 1.15
High-Cubic Bornite Nanoparticle-Enabled Photothermoelectric Catalysis Induces Dual Cuproptosis and Ferroptosis in Hepatocellular Carcinoma 0.20
A Self-Reinforcing Photonanocatalytic Platform Remodels Tumor Microenvironment for Synergistic Apoptosis/Ferroptosis Therapy in Liver Cancer 0.23
A Single-Metal-Doped Nanoplatform for Ferroptosis-Driven cGAS-STING Pathway Activation in Hepatocellular Carcinoma Immunotherapy 0.71
4 0.54
Reprogramming Disulfide Reduction in Endoplasmic Reticulum Uncouples Immune Evasion of Pancreatic Cancer 0.17
Thread‐Designed Vascular Scaffold with Magneto‐Optical Probes Capture and Elimination of Circulating Tumor Cells In Vivo 0.22
Personalized 3D Vaccine Integrates Immunotherapy and Antiangiogenic Therapy to Prevent Oral Squamous Cell Carcinoma Recurrence 0.07
Biohybrid Microrobot Enteric‐Coated Microcapsule for Oral Treatment of Colorectal Cancer 0.08
1 0.03
Extremely early genomic events and temporal order of esophageal squamous cell carcinogenesis: Longitudinal self-comparison of progressors and non-progressors 0.03
2 0.51
REGγ Links Inflammation to Fibrosis in Post-Necrotizing Enterocolitis Intestinal Strictures by Activating TGF-β/Smad3 Signaling 0.08
OPA1-mediated mitochondrial hyperfusion orchestrates YAP1 nuclear-translocation to sustain ameloblastoma stemness 0.43
1 0.73
Accurate and Early Diagnosis of NSCLC Using Aberrant Fragmentomic Features of Circulating Cell-Free Mitochondrial DNA. 0.73
3 1.33
MED: Multiplexed, Entropy-Driven Catalysis, Single-Nucleotide-Resolved ctDNA Detection 1.00
A Covalent Click Chemistry Chip for Highly Efficient Capture and Brightfield Identification of Circulating Tumor Cells 0.11
First Fluorescent Probe for TREX1 Enables Real-Time Tracking of DNA Repair and Immune Regulation in Cancer Cells 0.22
2 0.42
Self‐Assembled Nanoconjugates with Aggregation‐Induced Emission for Near‐Infrared II Imaging and Transcytosis‐Driven Cancer Therapy 0.08
HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking 0.33
1 0.56
CircFUT8 promotes proplatelet formation by interacting with IGF2BP2 and stabilizing TNS1 mRNA in megakaryocytes 0.56
1 0.05
Metastatic Lymph Node Burden and Invasive Tumour Features Inform First Recurrence Patterns After Curative-Intent Resection for Intrahepatic Cholangiocarcinoma 0.05
6 1.02
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration 0.05
Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways 0.04
Molecular insights into early malignant transition of hepatocellular carcinoma 0.09
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer 0.06
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study 0.03
Ketogenic diet inhibits glioma progression by promoting gut microbiota-derived butyrate production 0.75
9 3.53
CCL5hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer 0.85
PAK5-Mediated Suppression of β-Hydroxybutyrate Production Promotes Breast Cancer Metastasis and Can Be Overcome with Ketogenic Diet 0.08
Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells 0.09
LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer 0.83
Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer 0.15
TRIM49 Deficiency Stabilizes a Galectin-3/EGR1 Transcriptional Complex that Drives Invasiveness of Gastric Adenocarcinoma. 0.87
Mitochondrial Calcium Uniporter Links Acetyl-CoA Metabolism and H3K27 Acetylation to Maintain Glioblastoma Stem Cells 0.47
Targeting ATP7A-Dependent Copper Metabolic Homeostasis Induces Cuproptosis and Suppresses the Progression of Mutant KRAS-Driven Lung Cancer. 0.08
SRSF9 Forms Phase-separated Condensates to Promote Ovarian Cancer Progression by Inducing RNA Alternative Splicing that is Inhibited by m6A Modification. 0.12
1 0.20
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy 0.20
3 0.60
MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells 0.27
Paired patient-derived organoids reveal transcription factor-driven epigenetic remodeling in breast cancer metastasis 0.06
A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy 0.27
2 1.42
Dapk2 dysfunction leads to Mic60 lactylation and mitochondrial metabolic reprogramming, promoting lung cancer EGFR-TKI resistance and metastasis 0.68
The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi 0.74
1 0.03
Profiling the Chemical Exposomic Landscape of Esophageal Squamous Cell Carcinoma 0.03
1 0.01
Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation 0.01
1 0.15
Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic Cancer 0.15
5 1.70
SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers 0.03
KRAS-driven protein disulfide isomerase family A member 6 expression suppresses PRKR-like endoplasmic reticulum kinase-mediated immunogenic cell death to desensitise pancreatic ductal adenocarcinoma to immune checkpoint blockers 0.95
Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study 0.03
SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways 0.47
KIF1Bβ suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to attenuate the integrin pathway 0.22
3 0.17
Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma. 0.10
Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma. 0.02
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.05
1 0.11
Succinate preserves CD8+ T cell fitness to augment antitumor immunity 0.11
1 0.03
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. 0.03
4 1.44
CEP55 promotes prostate cancer progression via TPX2-dependent activation of AURKA–PI3K–AKT signaling and inhibition of ferroptosis 0.08
ZNF280A and ACRV1 Enhance Aerobic Glycolysis and Drive Ovarian Cancer Progression via the PI3K/AKT Signaling Pathway 0.29
Transmembrane BAX inhibitor motif containing 1 Inhibition of lysosomal degradation of TGF-β receptor 1 suppresses cellular senescence and hepatocarcinogenesis 0.57
The splicing factor SRSF6 mediates ferroptosis resistance in head and neck squamous cell carcinoma through induction of stearoyl-CoA desaturase 0.50
8 0.69
A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging 0.10
IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis 0.11
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates anti-tumor activity in metastatic castration-resistant prostate cancer 0.17
Proteogenomic characterization of cervical cancer identifies molecular subtypes predictive of clinical outcomes and subtype-specific targets 0.03
Reversing enhancer RNA–mediated IKBKE gene repression enables synthetic anticancer immunity in prostate cancer models 0.06
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I 0.11
C6orf223 promotes colorectal cancer growth and metastasis by facilitating PRMT5-MEP50 multiprotein complex assembling 0.10
S100a9 lactylation triggers neutrophil trafficking and cardiac inflammation in myocardial ischemia/reperfusion injury 0.01
4 1.27
Guanylyl Cyclase 2C–Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer 0.16
Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial 1.00
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. 0.03
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. 0.08
3 0.18
Surgery versus definitive radiotherapy after induction immunochemotherapy for stage II and III non–small cell lung cancer: A multicenter, pragmatic analysis 0.07
Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management 0.03
Lymph node dissection in neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter real-world study 0.07
3 0.16
Adaptive Protein Corona Nanoassemblies Couple Cytokine Signaling with Endogenous Antigen Transport for Systemic Cancer Immunity 0.10
Marine Natural Product Chagosendine C Induces Cuproptosis in Colorectal Cancer Cells by Targeting FDX1 0.03
Delivery of Peptide-LYTAC via Polyporus Polysaccharide Microneedles for Targeted CD47 Degradation and Enhanced Tumor Immunotherapy 0.03
1 0.08
ICAM1 mRNA entraps ILF2/ILF3 to inhibit transcription of EIF4E and global protein synthesis 0.08
2 0.50
Nanostapled Peptide Empowered Tumor Targeting and Programmed Release of a Therapeutic Peptide for Colorectal Cancer Therapy 0.44
Multiplexed Aptamer-Lattice Nanodevice for One-Step Phenotyping and Functional Quality Control of CAR-T Cells 0.07
3 0.28
Cell-free chromatin state tracing reveals disease origin and therapy responses 0.10
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance 0.00
The ubiquitin ligase KLHL6 drives resistance to CD8 T cell dysfunction 0.18
4 1.47
Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine–ZBTB5–mTORC1 axis 0.76
The lncRNA DAMER selectively guides mA-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer 0.08
THY1 cancer stem cells drive metastasis through a pseudohypoxic state shaped by neutrophil-derived mitochondria 0.08
SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer 0.56
28 7.39
Arid3b suppresses CD8 + T cell infiltration and function in microsatellite-stable colorectal cancer via Runx3 0.06
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial 0.06
HuR coordinates systemic aging through platelet infiltration 0.04
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial 0.80
D-π-A sensitized carbon dots as long-lived type-I/Ⅱ photosensitizers for NIR-excited hypoxia-regulated photodynamic therapy 0.10
PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma 0.78
NEK8 kinase-mediated lactate increase impairs antitumor immunity decreasing radiotherapy sensitivity in colorectal cancer 0.01
Dalpiciclib plus chidamide in HR + /HER2−advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial 0.87
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial 0.02
Amelioration of colorectal cancer-associated fibroblasts in immunosuppressive microenvironment by ferroptosis-based nanotherapy 0.03
Lactate derived from macrophages drives skin dermal fibroblasts phenotypic remodeling via MCT1-primed histone H3 lysine 23 lactylation in hypertrophic scar 0.89
USP10 promotes glioma stem cell maintenance and glioblastoma growth by antagonizing DTX3L-mediated SATB2 ubiquitination 0.03
Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial 0.04
Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial 0.05
Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer 0.11
Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy 0.05
Prodrug nanoplatform for triggering ferroptosis to eliminate senescent cells in age-associated pathologies 0.09
Lypd6b depletion promotes CD8+ T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer 0.03
Metabolic support protects mucosa from ferroptosis in radiation-induced mucositis 0.53
Bioorthogonal optimized virus immuno-nanomedicine (BOVIN) 0.06
Automated MRI system for clinically significant prostate cancer detection development validation and real-world implementation 0.58
Alternating current pre-treatment enhances multi-enzymatic activity of high-entropy alloy nanozymes that regulate metabolism for effective tumor immunotherapy 0.11
Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy 0.00
Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma 0.05
Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs 0.07
FAP+ fibroblasts orchestrate tumor microenvironment remodeling in renal cell carcinoma with tumor thrombus 0.64
Diabetes reshapes pancreatic cancer-associated endothelial niche by accelerating senescence 1.00
Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer 0.28
2 0.68
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 0.03
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial 0.64
1 0.63
Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy 0.63
1 1.00
Social interaction in mice suppresses breast cancer progression via a corticoamygdala neural circuit 1.00
3 0.24
Acoustic delivery of indocyanine green via biosynthetic gas vesicles for tumor photothermal therapy 0.06
Optineurin binding to the novel interacting partner Junction plakoglobin prevents muscle atrophy in mice 0.05
Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response. 0.14
1 0.11
ZBP1 Drives CD8+ T cell-mediated anti-tumor immunity in head and neck squamous cell carcinoma 0.11
3 0.79
Mitochondrial fusion heterogeneity drives bidirectional tumor phenotypic transition in combined hepatocellular–cholangiocarcinoma 0.65
Loss of UFL1 drives chromosome instability and tumorigenesis of prostate cancer 0.10
Metabolic stress conditions dictate MAPKAPK2-dependent efficiency of MEK1/2 inhibition in colorectal carcinoma 0.04
2 1.38
Survival Outcomes of Microwave Ablation Compared with Repeat Liver Resection in the Treatment of Recurrent Intrahepatic Cholangiocarcinoma. 0.71
Efficacy and Safety of Microwave and Radiofrequency Ablation in the Treatment of Hyperparathyroidism in Older Individuals: A Multicenter Prospective Study. 0.67
9 3.61
SRSF3 determines Treg cell fate in antitumor immunity and autoimmunity 0.25
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent–programmed CAR T cells 0.92
Epithelial plasticity shapes intratumoral heterogeneity and cell lineages in early-stage lung cancer 0.31
circHERC1—A telomerase activator 0.06
Biohybrid nanorobots induce lactate isomer conversion to reverse the immune environment and promote tumor therapy 0.10
Enhanced FOS expression improves tumor clearance and resists exhaustion in NR4A3-deficient CAR T cells under chronic antigen exposure 0.74
Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC 0.38
USP13 stabilizes NLRP3 to facilitate inflammasome activation by preventing TRIM31-mediated NLRP3 ubiquitination and degradation 0.10
HLF transactivates TFEB to promote gallbladder cancer stem cells’ self-renewal and determines tumor response to distinct therapies 0.75
3 0.16
Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia 0.03
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome 0.03
Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation 0.11
2 1.02
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial 0.02
Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis 1.00
5 0.49
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study 0.07
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China 0.33
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 0.02
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China 0.03
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial 0.04
3 0.17
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial 0.04
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial 0.07
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial 0.07
3 0.12
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.01
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma 0.06
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.05

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.